Digest Network Come funziona
Network
/
Società
Ar
Non verificato

Arialys Therapeutics

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaPsichiatriaSalute

6 comunicati stampa

Guarda tutti i comunicati
25/09/2025
Industria
Psichiatria
Salute
HIV, AIDS e malattie autoimmuni
Farmaceutica
Biotecnologia
Arialys Therapeutics Receives FDA Rare Pediatric Disease Designation for ART5803 to Treat Anti-NMDA Receptor Encephalitis
Fonte
Arialys Therapeutics
Emittente
Business Wire
1.00
0
17/06/2025
Psichiatria
Scienza
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Industria
Arialys Therapeutics Publishes Preclinical Data in Nature Communications Supporting ART5803 as a First-in-Class Precision Therapeutic for Anti-NMDA Receptor Autoimmune Neuropsychiatric Disease
Fonte
Arialys Therapeutics
Emittente
Business Wire
1.00
0
26/02/2025
Biotecnologia
Sanità
Salute
Farmaceutica
Psichiatria
Scienza
Medicina - Varie
Industria
Arialys Therapeutics Initiates MAD Cohorts Having Completed All Planned SAD Cohorts in a Phase 1 Study of ART5803 for the Treatment of Autoimmune Neuropsychiatric Disease
Fonte
Arialys Therapeutics
Emittente
Business Wire
1.00
0
22/10/2024
Mercato del lavoro
Psichiatria
Scienza
Biotecnologia
Sanità
Salute
Farmaceutica
Arialys Therapeutics Appoints Sankalp Gokhale, M.D., Chief Medical Officer
Fonte
Arialys Therapeutics
Emittente
Business Wire
1.00
0
10/10/2024
Psichiatria
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Arialys Therapeutics Announces First Participants Dosed in a Phase 1 Clinical Trial of ART5803, a Precision Medicine for the Treatment of Autoimmune Neuropsychiatric Diseases
Fonte
Arialys Therapeutics
Emittente
Business Wire
1.00
0
25/06/2024
Biotecnologia
Psichiatria
Salute
Farmaceutica
Mercato del lavoro
Arialys Therapeutics Appoints Peter Flynn, Ph.D., President and Chief Executive Officer
Fonte
Arialys Therapeutics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0